US Weekly IPO and SPAC Monitor: Lab-grown Diamond Producer Adamas One

There is just one small deal scheduled to price, lab-grown diamond producer Adamas One (JEWL) in the short Thanksgiving week. There is a chance some micro-caps may IPO they have been looking to price on a “day-to-day” basis as brokers look to shift deals in the pipeline to investors with the stock market surge this week. There are several large issuers in the pipeline, as well as sizable new filings from insurer Skyward Specialty (SKWD) and oil and gas companies TXO Energy Partners (TXO) and BKV Corp (BKV), … Continue reading “US Weekly IPO and SPAC Monitor: Lab-grown Diamond Producer Adamas One”

US Weekly IPO and SPAC Monitor: BullFrog AI and Acrivon Therapeutics

There is just one small deal scheduled to price, Nano-cap BullFrog AI Holdings (BFAI) is developing an analytical AI/ML platform for drug development. Precision oncology biotech Acrivon Therapeutics (ACRV) may also price, after delaying its $100 million IPO. Last week we were surprised by holdover IPOs and one, Intensity Therapeutics (INTS) postponed. There is a chance some micro-caps may IPO they have been looking to price on a “day-to-day” basis as brokers look to shift deals in the pipeline to investors with the … Continue reading “US Weekly IPO and SPAC Monitor: BullFrog AI and Acrivon Therapeutics”

US Weekly IPO and SPAC Monitor: Biotech Acrivon Therapeutics and Online Games Developer Snail

There are two deals due to price in the week ahead, Precision oncology biotech Acrivon Therapeutics (ACRV) plans to raise $100 million and holdover Intensity Therapeutics (INTS) plans to raise $10 million  Online games developer Snail is also expected to Price. There is a chance some micro-caps may IPO they have been looking to price on a “day-to-day” basis as brokers look to shift deals in the pipeline to investors. The dismal IPO market continued with no new IPO pricings last week in fact … Continue reading “US Weekly IPO and SPAC Monitor: Biotech Acrivon Therapeutics and Online Games Developer Snail”

US Weekly IPO and SPAC Monitor: Following Mobileye’s Strong Debut Watch for Refreshed Filings

Following the strong debut of the Intel Mobileye IPO there are no confirmed IPOs scheduled for the week ahead but some shuffling of papers for a number of micro-caps on the calendar looking to price on a “day-to-day” basis. Often run ups in the stock market as we have seen in the past week bring a few out as brokers look to shift deals in the pipeline to investors. A feature of the IPO market this year is the many … Continue reading “US Weekly IPO and SPAC Monitor: Following Mobileye’s Strong Debut Watch for Refreshed Filings”

US Weekly IPO and SPAC Monitor: Intel’s Mobileye, Biotech’s ASP Isotopes and Intensity Therapeutics

A feature of the IPO market this year is the many names coming up for pricing and being delayed. No surprise with 87% issued in the last year down according to Dealogic. We have the Intel Mobileye IPO listing this week.  MBLY is only floating 5% of its basic shares outstanding, well below the typical 15% after the market took to INTC last week. Two holdovers are also expected to debut in the week ahead. Isotope enrichment company ASP Isotopes … Continue reading “US Weekly IPO and SPAC Monitor: Intel’s Mobileye, Biotech’s ASP Isotopes and Intensity Therapeutics”

US Weekly IPO and SPAC Monitor: Gene editing Biotech Prime Medicine and Molybdenum Enricher Aerodynamic Separation Process

We are seeing a little activity in IPO land. A few deals are scheduled to price in the week ahead, and many still on the back burner. Gene editing biotech Prime Medicine (PRME) would be the first sizable IPO of the fourth quarter. Aerodynamic Separation Process (ASP) focusing on the commercialization of enriched Molybdenum-100 plans to list. Three holdovers from the past week are scheduled to price; Beamr Imaging (BMR), Intensity Therapeutics (INTS) and Alopexx (ALPX). Intel’s Mobileye (MBLY) will … Continue reading “US Weekly IPO and SPAC Monitor: Gene editing Biotech Prime Medicine and Molybdenum Enricher Aerodynamic Separation Process”

US Weekly IPO and SPAC Monitor: Biotech Alopexx, Software Companies Beamr and Castellum

The IPO drought continues to worsen along with global liquidity. Fund managers, investors and deal makers are obviously reluctant to wade into new IPOs. On the agenda is Beamr (BMR), an Israeli video encoding and image optimization software provider, OTC-listed intelligence analysis, software development company Castellum (CTM) and infectious disease biotech Alopexx (ALPX). The fourth quarter started off quietly week with just one SPAC priced and three small issuers submitted initial filings. A new SPAC plans to target the new … Continue reading “US Weekly IPO and SPAC Monitor: Biotech Alopexx, Software Companies Beamr and Castellum”

US Weekly IPO and SPAC Monitor: Intel’s Mobileye Filed for an IPO in Quiet Period

No surprise after the disaster of the three major US stock indexes ugly closes Friday to finish off a disastrous September and the IPO market there are currently no IPOs scheduled for the first week of October. The biggest news of the week came from Intel’s Mobileye (MBLY), which filed for an IPO we estimate could raise up to $2.5 billion. The third quarter was worst third quarter for new issuers in over a decade, with 25 IPOs raising $2.4 billion as … Continue reading “US Weekly IPO and SPAC Monitor: Intel’s Mobileye Filed for an IPO in Quiet Period”

US Weekly IPO and SPAC Monitor: Biotech Intensity Therapeutics, Chinese YanGuFang and Japanese Lead Real Estate

Coming into end of quarter IPO pricing expect from two Asian issuers and a biotech. Chinese producer of oat and grain products YanGuFang (YGF), Japanese luxury real estate developer Lead Real Estate (LRE) and Oncology biotech Intensity Therapeutics (INTS).  There may also be a number of small deals that have been expected but have not priced. Another quiet week as IPO continue to dry up in this risk off market. One NYSE American uplisting Loop Media (LPTV) priced at the … Continue reading “US Weekly IPO and SPAC Monitor: Biotech Intensity Therapeutics, Chinese YanGuFang and Japanese Lead Real Estate”